Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00509769
Status:
COMPLETED
Last Update Posted:
2013-04-02
First Post:
2007-07-27
Brief Title:
A Study of Trastuzumab Emtansine Trastuzumab-MCC-DM1 Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 HER2-Positive Metastatic Breast Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Single-arm Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a multi-institutional open-label single-arm Phase II study of trastuzumab emtansine T-DM1 administered by intravenous IV infusion to patients with human epidermal growth factor receptor 2 HER2-positive metastatic breast cancer MBC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None